This drug Became a Boon for Cancer Patients – Dostarlimab
Cancer is a deadly disease that afflicts many people. Medical science has been trying to find medicine or vaccine for many years to prevent this disease. In such a situation, a remarkable achievement has come in front of the researchers, this achievement has completely surprised them.
Recently this research was published in the Journal of Medicine in New England, that during a research, 18 patients with rectal cancer were given the drug Dostarlimab for 6 months.
When all the tests and scanning of those 18 patients were completed after the prescribed period, even the doctors were stunned to see the result that no cancer of any kind was present in their body anymore. It is endorsed by drug manufacturer Glaxo SmithKline.
The drug Dostarlimab, a monoclonal antibody drug that is already validated in the UK for the treatment of endometrial cancer, is sold under the brand name Gemperli. The drug dostarlimab was approved for medical use in the United States and the European Union in April 2021.
During the clinical trial at Memorial Sloan Kettering Cancer Center in New York on June 6, this medicine has given very good results, so now this medicine will be used for permanent treatment of cancer disease.